authors
- Hughes, TP
- Leber, Brian
- Cervantes, F
- Spector, N
- Pasquini, R
- Clementino, NCD
- Schwarer, AP
- Dorlhiac-Llacer, PE
- Mahon, F-X
- Rea, D
- Guerci-Bresler, A
- Kamel-Reid, S
- Bendit, I
- Acharya, S
- Glynos, T
- Dalal, D
- Branford, S
- Lipton, JH
Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results
Journal Articles
- Overview
- Research
- Identity
- Additional Document Info
- View All
Overview
status
publication date
- November 2017
has subject area
- 1103 Clinical Sciences (FoR)
- 1112 Oncology and Carcinogenesis (FoR)
- Antineoplastic Agents (MeSH)
- Cross-Over Studies (MeSH)
- Fusion Proteins, bcr-abl (MeSH)
- Humans (MeSH)
- Imatinib Mesylate (MeSH)
- Immunology (Science Metrix)
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive (MeSH)
- Protein Kinase Inhibitors (MeSH)
- Pyrimidines (MeSH)
published in
- Leukemia Journal